Good
Partially Aligned
Patient Risk:
Medium
Summary
The evaluated set includes a statement specifically about urgent help for suicidal thoughts, which is consistent with the label’s boxed warning and counseling/monitoring requirements for emergence of suicidality, especially early and during dosage changes. However, multiple other claims provided in the list are not supported or contradicted by the supplied label excerpts (which focus on suicidal thoughts/behaviors in pediatric/young adults), so overall alignment is limited to the suicidal-risk portion.
Category Scores
Accurate Statements
Get help urgently if suicidal thoughts develop while taking trazodone.
Boxed Warning (Suicidal Thoughts and Behaviors in Pediatric and Young Adult Patients); Section 5.1 (monitor all antidepressant-treated patients, especially during initial months and at dosage changes); Section 17 (advise patients/caregivers to look for emergence of suicidality, especially early and when dosage is adjusted up or down, and report to healthcare provider).
Unsupported Statements
Seek prompt medical advice if dream changes occur with confusion.
Not supported by the supplied prescribing information excerpts (which cover boxed warning/monitoring for suicidality in pediatric/young adults).
Seek prompt medical advice if dream changes occur with severe agitation.
Not supported by the supplied prescribing information excerpts.
Seek prompt medical advice if dream changes occur with hallucinations.
Not supported by the supplied prescribing information excerpts.
Seek prompt medical advice if dream changes occur with behavior that feels out of character.
Not supported by the supplied prescribing information excerpts.
Get help urgently if serious mood changes develop while taking trazodone.
The supplied label excerpts specifically address suicidal thoughts/behaviors and monitoring for clinical worsening/emergence of suicidal thoughts and behaviors; they do not separately support a generalized instruction for 'serious mood changes' as written.
Stopping trazodone suddenly can lead to rebound sleep problems in some people.
Not supported by the supplied prescribing information excerpts.
For many users, dream side effects lessen as the body adjusts.
Not supported by the supplied prescribing information excerpts.
Do not mix trazodone with other sedatives unless the clinician directs you.
Not supported by the supplied prescribing information excerpts.
Avoid alcohol with trazodone.
Not supported by the supplied prescribing information excerpts.
People may report vivid dreams/nightmares after starting trazodone or after dose changes.
Not supported by the supplied prescribing information excerpts.
The exact mechanism for trazodone-related dream changes isn’t always clear.
Not supported by the supplied prescribing information excerpts.
Dreaming is most strongly associated with REM sleep.
Not supported by the supplied prescribing information excerpts.
Clinicians may consider sleep-focused treatment if dream effects are unacceptable.
Not supported by the supplied prescribing information excerpts.
Contributing issues such as anxiety, sleep apnea, restless legs, or substance use can strongly affect dreaming.
Not supported by the supplied prescribing information excerpts.
Contradictions
Important Omissions
The label emphasizes monitoring for clinical worsening and emergence of suicidal thoughts/behaviors, especially during the initial few months of therapy and at times of dosage changes, and advises counseling caregivers to monitor and alert the healthcare provider.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The suicidal-thought urgency instruction aligns with the label’s boxed warning/counseling concept, but the overall set of claims includes many dream-related and alcohol/sedative/discontinuation recommendations that are not supported by the provided label excerpts, which could dilute or distract from the specific boxed-warning monitoring/counseling for suicidality.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Only the suicidal-thoughts urgent help statement is supported by the supplied FDA label excerpts; the majority of other provided claims are not supported by those excerpts and therefore cannot be confirmed as on-label based on the provided information.
Suggested Improvement
Limit claims to label-supported suicidality monitoring/counseling (especially early treatment and during dose adjustments) and avoid making dream/behavior/alcohol/sedative/discontinuation recommendations unless supported by the relevant sections of the prescribing information not provided here.